NCT03866382 2026-03-18
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
13 trialsNCT03338790 2026-01-27
CheckMate 9KD
Bristol-Myers Squibb
Phase 2 Completed
NCT02985957 2025-12-22
CheckMate 650
Bristol-Myers Squibb
Phase 2 Completed
NCT04019964 2025-10-23
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT05445609 2025-09-19
Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
Emory University
Phase 2 Suspended
NCT04709276 2025-09-11
CHAMP
Duke University
Phase 2 Active not recruiting
NCT03637543 2025-08-14
Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer
Beth Israel Deaconess Medical Center
Phase 2 Active not recruiting
NCT05655715 2024-10-16
CheckPRO
Herlev and Gentofte Hospital
Phase 2 Completed
NCT04159896 2024-07-16
ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT03554317 2024-02-20
COMBAT-CRPC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT05150236 2023-12-15
ANZUP2001
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Unknown
NCT02601014 2022-02-03
STARVE-PC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03040791 2021-08-26
ImmunoProst
Hospital Moinhos de Vento
Phase 2 Unknown